Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Inclusion * Patients must have a diagnosis, either cytologic or histologic, of melanoma of the iris, ciliary body and/or choroid * Patient's tumor must exhibit monosomy 3 and/or 8q amplification as determined by karyotype, comparative genomic hybridization (CGH), polymerase chain reaction (PCR)-based microsatellite, and/or Fluorescence in situ Hybridization (FISH) analysis; tissue or cells for analysis can be obtained at enucleation, resection, or by fine needle aspirate (FNA). * Patients must have undergone adequate primary therapy; this can include enucleation, brachytherapy, proton beam radiotherapy, stereotactic irradiation, trans-scleral local resection, transretinal resection or diode laser thermotherapy * Patients must have had chest X-ray and hepatic ultrasound or other imaging methods such as CT or MRI to eliminate distant disease * Patients must have a performance status (ECOG) of \< 2 * Patients must be entered within 56 days of completing primary therapy * White blood count (WBC) ≥ 3.0 x 10\^9/L * Neutrophils ≥ 1.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * international normalized ratio (INR) and partial thromboplastin time (PTT) \< 1.5 x upper limit of normal * Hemoglobin ≥ 10 gm/100 ml * Creatinine ≤ 2 mg/dl * Bilirubin (total) ≤ 1.5 mg/dl * Alanine transaminase (ALT) ≤ 1.5 x upper limit of normal * Alkaline phosphatase ≤ 1.5 x upper limit of normal * Aspartate aminotransferase (AST) ≤ 1.5 x upper limit of normal * Patients must not have received any other system…